Regulatory Daily Summary
Regulatory Daily Summary: What Happened on November 13, 2026
EMA backs seven medicines as FDA approves Pimjetmi
The FDA also faces conflicting accounts over its priority-voucher pilot. Tandem won clearance for a longer-wear insulin-pump setup.
Today in brief
The EMA’s drug committee recommended seven medicines for authorization and supported 11 indication extensions at its November meeting.1
The FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor.2
Reuters reported that the FDA had stopped reviewing and awarding new National Priority Vouchers, while HHS said the pilot continues.34
EMA recommends seven medicines, including two for lung cancer
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended marketing authorization for seven medicines at its November 9-12 meeting.1 They include Aumseqa and Zybrivo for non-small cell lung cancer, Baxfendy for inadequately controlled hypertension, and two insulin-aspart biosimilars for diabetes in people aged one year and older.1
The committee backed extending Gazyvaro for some adults with active, moderate-to-severe systemic lupus erythematosus and Isturisa for endogenous Cushing’s syndrome in children and adolescents aged six and older.1 It also recommended indication extensions for nine other medicines already authorized in the European Union, bringing the meeting’s total to 11 extension opinions.1
The committee recommended a 100-milligram dapivirine vaginal ring that can be replaced every three months instead of monthly.1 It maintained recommendations against authorizing two medicines after reconsidering its initial opinions.1
Accounts conflict over whether FDA’s voucher pilot has stalled
Reuters, citing sources and internal documents, reported that the FDA had stopped reviewing and awarding new National Priority Vouchers, though applications remained open.345
A Department of Health and Human Services spokesperson said FDA staff continue to assess applications, meet commitments for existing vouchers, and review feedback from a June hearing.345 The pilot began in June 2025 under then-commissioner Marty Makary, with a target of one- to two-month reviews for eligible products.34
Reports put the number of voucher recipients at 22, including 12 approvals and one rejection, with nine drugs still in the program.345
Also worth knowing
-
The FDA cleared Tandem Diabetes Care’s Mobi insulin pump for a tubeless setup that can be worn for up to seven days. Tandem expects a full U.S. rollout in the first half of 2027.6
-
The FDA posted early alerts for two device removals. Intersurgical advised customers to stop using the affected devices, while Arrow International told users to quarantine and return certain products.7
-
Novo submitted a medicine for sickle cell disease.8
Also published
- The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach BioPharm International
- Pharmaceutical Executive Daily: FDA Shelves CNPV Program Pharmaceutical Executive
- Pay Transparency in Life Sciences: Staying Ahead of Emerging Regulatory Complexity MedCity News
- Overton’s iffy FDA confirmation; a slashed US IPO PharmaVoice
- FDA puts commissioner’s priority voucher framework on ice Pharmaceutical Technology
- Inspection readiness is now a commercial question pharmaphorum
- Are Makary's priority review vouchers about to be canned? pharmaphorum